Overview

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Status:
Completed

Trial end date:
2014-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the intraocular pressure (IOP) lowering efficacy and the safety and tolerability profile of trabodenoson ophthalmic formulation compared to timolol maleate ophthalmic solution 0.5% in adults with ocular hypertension (OHT) or primary open-angle glaucoma (POAG) who are already receiving treatment with latanoprost ophthalmic solution 0.005% once every evening (QPM).

Phase:

Phase 2

Details

Lead Sponsor:

Inotek Pharmaceuticals Corporation

Treatments:

Latanoprost
Ophthalmic Solutions
Tetrahydrozoline
Timolol